Drug Interaction Report

GENERALLY AVOID: Concomitant administration with inhibitors of the organic anion transporter 3 (OAT3) may increase the plasma concentrations of seladelpar, which is a substrate of this renal transporter. Administration of the OAT3 inhibitor probenecid (500 mg four times daily) to healthy subjects on days 1 through 4, with a single dose of seladelpar (10 mg) administered on day 2 resulted in an increase of seladelpar's systemic exposure (AUC) and maximum plasma concentration (Cmax) of 2- and 4.69-fold, respectively. Additionally, the mean cumulative urinary excretion of seladelpar was unquantifiable in the presence of probenecid, compared to 2.1 mcg in the absence of probenecid.

MANAGEMENT: Concurrent use of seladelpar with OAT3 inhibitors should generally be avoided.

GENERALLY AVOID: The consumption of alcohol during therapy with leflunomide may potentiate the risk of liver injury. Leflunomide has been associated with hepatotoxicity, including elevated liver transaminases, hepatitis, jaundice/cholestasis, hepatic failure, and acute hepatic necrosis,

MANAGEMENT: Patients should be advised to avoid excessive alcohol use during leflunomide treatment.